Key result
Cardiac valve calcification was present in 49% of hemodialysis patients and was associated with higher left ventricular mass index, particularly when both valves were calcified.
Why the study?
Is cardiac valve calcification associated with left ventricular hypertrophy in hemodialysis patients?
Cross-Sectional (n=65)
Is cardiac valve calcification associated with left ventricular hypertrophy in hemodialysis patients?
Cardiac valve calcification is associated with left ventricular hypertrophy in hemodialysis patients, particularly when both mitral and aortic valves are involved.
Answers are grounded in this paper and cite their sources.
Valve calcification may mark higher LV mass in hemodialysis patients; extends observational associations but leaves causality and intervention effects open.
Cardiac valve calcification (VC) is a common finding in end-stage renal disease patients. It was shown recently that VC is an independent predictor for all-cause and cardiovascular mortality in peritoneal dialysis patients. In hemodialysis (HD) patients, VC was associated with all-cause and cardiovascular mortality, but after adjusting for other cardiovascular risk factors and complications, as well as left ventricular mass index (LVMI), it lost significance. The aim of the study was to assess the relationship between VC and left ventricular hypertrophy in hemodialysis patients. Echocardiographic examination with mitral and aortic valves assessment and LVMI calculation was performed in 65 HD patients ages 49 ± 12, with duration of HD therapy 38 ± 32 months. VC were found in 32 of 65 patients (49%)—Group VC(+), mitral valve calcifications (MVC) in 10, aortic valve calcifications (AVC) in 9, and both valves calcifications (MVC + AVC) in 13 patients. Patients with VC were older, on HD therapy were longer, had higher systolic and pulse pressure, and had higher LVMI. Patients with both VCs had the highest LVMI. No significant differences were found with respect to Ca, P, PTH, and mean Ca × P product, but the incidence of Ca × P product above 4.43 mmol2/L2 was higher in VC(+) compared with those without VCs. VC coexists with left ventricular hypertrophy, particularly when both valves are calcified. Even short-lasting incidents of increased Ca × P product may lead to cardiac VC.
No takes yet. Share an insight, caveat, or question.
Stróżecki et al. (2005) conducted a cross-sectional in End-stage renal disease on hemodialysis (n=65). Cardiac valve calcification vs. No cardiac valve calcification was evaluated on Left ventricular mass index (LVMI). Cardiac valve calcification was present in 49% of hemodialysis patients and was associated with higher left ventricular mass index, particularly when both valves were calcified.
Synapse has enriched 10 related papers. Consider them for comparative context: